Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654972 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1 study, sponsored by Eli Lilly and Company.
- Not yet
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT07654972: Clinical Trial Phase 1 study, sponsored by Eli Lilly and Company.
NCT07654972 is a Phase 1 study that has not yet begun recruiting, run by Eli Lilly and Company. The registered enrollment target is 108 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07654972, a Phase 1 study, has not yet begun recruiting, sponsored by Eli Lilly and Company.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).
Primary Outcome
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
Interventions
- DRUG Placebo
- DRUG LY4174794
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-04 |
| Phase | Phase 1 |
What is known before NCT07654972 opens enrollment
NCT07654972 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07654972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07654972 about?
NCT07654972 is a clinical study titled "A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy". The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Particip...
What is the current status of trial NCT07654972?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2026-06. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07654972?
The interventions under investigation include: Placebo (DRUG), LY4174794 (DRUG).
Who is sponsoring clinical trial NCT07654972?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07654972's enrollment target sits among peer trials
108 523rd of 2000 higher than 1,470 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia